Hypertension, or high blood pressure, is a common health condition that affects millions of people in Europe and around the world. It is a major risk factor for many serious health conditions, including stroke, heart attack, and kidney disease. Hypertension is also a major contributor to the burden of disease in Europe, with an estimated 2 million deaths attributable to hypertension each year. This article will explore the impact of hypertension on European society, focusing on the prevalence, risk factors, and health outcomes associated with the condition.
Hypertension is a major public health issue in Europe, with an estimated 45 million people affected by the condition. Hypertension is more common in older age groups, with the highest prevalence among those aged 65 and over. Hypertension is also more common in men than women, and in those living in lower socioeconomic groups.
The risk factors for hypertension are well-established and include lifestyle factors such as smoking, physical inactivity, and poor diet. Other risk factors include age, family history, and certain medical conditions such as diabetes and kidney disease.
Hypertension is a major risk factor for a range of serious health conditions, including stroke, heart attack, and kidney disease. Hypertension can also lead to an increased risk of cognitive decline, dementia, and depression. Hypertension is also associated with an increased risk of death, with an estimated 2 million deaths attributable to hypertension each year in Europe.
The impact of hypertension on European society is significant, with the condition leading to an increased burden of disease, increased health care costs, and reduced quality of life. Hypertension is also associated with an increased risk of disability, with an estimated 10 million people in Europe living with a disability caused by hypertension.
The prevention and management of hypertension is essential in order to reduce the burden of the condition on European society. Lifestyle modification is the cornerstone of hypertension management, with a focus on smoking cessation, physical activity, and healthy eating. Other management strategies include the use of medications, such as ACE inhibitors, beta-blockers, and diuretics.
Hypertension is a major public health issue in Europe, with an estimated 45 million people affected by the condition. The impact of hypertension on European society is significant, with the condition leading to an increased burden of disease, increased health care costs, and reduced quality of life. The prevention and management of hypertension is essential in order to reduce the burden of the condition on European society. Lifestyle modification is the cornerstone of hypertension management, with a focus on smoking cessation, physical activity, and healthy eating. Other management strategies include the use of medications, such as ACE inhibitors, beta-blockers, and diuretics.
1.
A single-cell analysis reveals a distinctive immunosuppressive tumor microenvironment in kidney cancer brain metastases.
2.
The FDA approves Enhertu for HER2-positive cancers, regardless of tumor type.
3.
Cancer diagnosis does not spur improvements to survivors' diets or eating habits
4.
According to a study by Amrita Hospital in Kochi, cancer mortality is rising among Indian women while declining for men.
5.
A garden can save your life
1.
Reshaping the Battlefield Through Tumor Microenvironment Modulation for Cancer Therapy
2.
Understanding Epoetin and Its Role in Treating Chronic Kidney Disease
3.
Biologic Therapies for Cutaneous Immune-Related Adverse Events in the Era of Immune Checkpoint Inhibitors
4.
Cracking the Code of Subdural Hematomas: Modern Strategies for Optimal Care
5.
Imaging in Peritoneal Neoplasms: Diagnostic Advances and Multimodal Treatment Strategies
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Panel Discussion on Clinical Trial End Point for Tumor With PPS > 12 months
2.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V
3.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion
4.
Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation